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Valorization
Background
Cancer is a leading cause of death worldwide. The causes, characteristics, risk factors and
occurrence of cancer can vary greatly, requiring a constant development of new therapies.
Radiotherapy is one of themain treatments for cancer, in which different technologies and
types of radiation can be used, such as proton therapy.
In the last decennia, the number of proton therapy centers treating and under
construction has increased exponentially, as ameasure to providemore precise treatment
modality for malign tumours. The characteristic dose distribution of a proton beam in
the human body has the potential to decrease short and long term secondary effects of
radiation. However, there is a lack of evidence supporting this theoretical advantage of
proton therapy, only a few comparison studies indicate its superior outcome compared to
x-ray radiotherapy (partially summarized inChapter 1), mostly for children. A newpatient
selection system that can help bring light to this topic is the dutchmodel based approach:
for each patient with a proton indication, photon (x-ray) and proton treatment plans are
calculated and compared, and based on the radiation toxicity levels to the main organs-
at-risk (OARs), a choice is made between both radiotherapy modalities. This model might
have an important role in providing quantitative evidence of proton therapy’s ability to
better spare the OARs near a tumour.
Computed tomography (CT) imaging plays a crucial role in radiotherapy treatments, since
the treatment plan ismade based on the tissue compositions and densities extracted from
the processing of each patient CT image. Nevertheless, there is an uncertainty associated
with the different CT imaging, scanners and post-processingmethods, which are specially
relevant for proton therapy, when compared to conventional x-ray radiotherapy, because
proton beams deposit most of their energy at the end of a track. To account for such
uncertainties, margins are added to the tumour volume to assure that the whole malign
mass is irradiatedwith the necessary dose, however thismeasure has the cost of increasing
the dose to the surrounding healthy tissues.
Monte Carlo (MC) methods are considered the gold-standard for simulations of particle
transport and interactions with matter, due to its complex implementation of physical
models and libraries. In radiotherapy, MC techniques are needed to better predict the
dose distribution in a patient, using directly or indirectly the information extracted from
a CT image. While analytical methods may overlook small differences caused by tissues’
miss-assignment of atomic composition and density, using MCmethods these effects will
be taken into account and contribute for the final dose. Besides, MC techniques are used
to obtain the linear-energy-transfer (LET) distribution of different particle beams, and can
also deal with moving geometries and help to understand inter-play effects between a
moving beam and a moving target. MC’s biggest down-side is the computational time
needed for accurate simulations, which is highly dependent on the geometry complexity
and size, and the number of particles simulated. Nevertheless recent developments in
the computer industry have made it possible for vendors of treatment planning systems
(TPSs) to start implementing (fast) MCmodels.
Products and innovation
In this thesis, methodologies of improving accuracy in proton therapy have been studied.
Dual-energy CT dose calculations: Wewere the first group to develop a platform where
dual-energy computed tomography (DECT) images could be used from end-to-end to
perform MC dose calculations, a method still not implemented in any commercially
available TPS. With this platform, differences in the range of protons using standard
images and this new up-rising technology were investigated for phantoms, in which
ground truth is known, and on a patient case. For the latter, clinical relevant differences
were observed.
Moreover, different DECT modalities and methods were studied through-out this thesis,
aiming to investigate the impact of DECT imaging on proton range and dose calculations,
and to provide recommendations between DECT systems.
Full implementation of DECT in a TPS is not trivial if the vendor decides to use both
DECT images as input. For this, DECT-specific calibrations are needed and the vendor
needs to choose one from the different methods published in the last decade, for which
validation has been performed in phantom studies using tissue mimicking inserts and
animal tissues. An alternative is to calculate a weighted sum of both DECT images (called
pseudo-monoenergetic image, PMI), or using CT scanners’ own software to convert the
DECT images into mass-densities or relative electron densities, that can also be given as
input for the TPS.
The wide choice of possibilities dealing with DECT images makes it more difficult for
DECT to be implemented on clinical practice, since numerous software and methods are
available, and for a TPS vendor to choose one and implement it.
Proton system with a multi-leaf collimator: We were also the first group to model a
proton therapy system with an unique multi-leaf collimator at the end of the beam line
(the Adaptive Aperture™, a product of MevionMedical Systems, Inc., Littelton, USA) used
to improved the sharpness of proton beams, hence decreasing the dose given laterally
to healthy tissues and OARs. The development of the beam model was done parallel
to the clinical implementation of this component and in close collaboration with the
manufacturer, enabling the study of several features from this device and even investigate
how to improve it. Thismodel aims also to be used as an independentMCdose calculation
platform with respect to the available TPS.
Furthermore, we also proved the feasibility of using this multi-leaf collimator combined
with a precise imaging platform for irradiation of small-animals, a complete different field
for which the system was not intended, greatly expanding its research capabilities. Pre-
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VALORIZATION
clinical research is a corner stone of scientific developments in radiotherapy, from which
new methodologies can be translated to clinical practice. Proton therapy is no exception
and there is a need for pre-clinical experiments, however the cost of building a dedicated
system is too high for most research facilities, making the option of adapting an existing
clinical system very attractive. In this field, pre-clinical studies can help understand the
biological impact of proton beams compared to standard radiotherapy, the impact on cell
damage when using proton beam at different dose rates, or to investigate the potential
benefit of combining proton therapy with immunotherapy, dose enhancers and other
drugs.
Challenges and future perspectives
The translation of proton therapy from physics institutes and laboratories to clinical
practice has brought numerous topics of research for the scientific community. The main
goal is to assure the quality of treatment, in which the entire tumour is irradiated with the
necessary dose to treat the patient, and at the same time theminimum amount of healthy
tissue is irradiated with high doses.
On the other hand, particle therapy centers are considered the single most expensive
specialized medical tool for cancer treatment, where treatment cost greatly exceeds the
one from conventional radiotherapy. For this reason, a concern has been raised that
proton therapywill be overused for common cancer for which evidence for proton therapy
is still unclear, due to the potential profit it may bring for the medical institution. To
decrease the cost of a proton therapy center, more compact single-room facilities have
appear on themarket in the last years,making its constructionmore affordableworldwide.
With respect to the topics investigated in this thesis, DECT potential improvement over
single-energy CT might not be good enough to achieve the level of uncertainty desired
in tissue segmentation and proton range prediction. Hence, other technologies have
appeared as potential better alternatives, such as triple-energy CT or spectral CT. Another
alternativemight be the use of protonbeams for imaging, calledprotonCT, which provides
a directmeasurement of tissue’s proton stopping powers. For either case, there is a need to
verify themethod used bymeans of in vivomeasurements of proton range, without which
final validation of the methods is not achievable. These methods discussed in Chapter 7,
are still under-development and not yet at a level of becoming part of clinical practice.
Furthermore, during the course of a treatment that can take up to seven weeks, the
patient’s anatomy can change drastically while the tumour can shrink/expand or move
to a different location. It is for this reason necessary to do treatment adaption with the
help of weekly or daily imaging. Currently, centers that do treatment adaptation, do it
by recalculating the plan after seeing relevant differences on interfractions CT. However,
intrafaction motion or irregularities are not measured. A future goal for treatment
adaptation would be to do it online, in which the patient is positioned, the plan is partially
delivered and with in vivomeasurements the dose is verified and the plan adapted in loco
if needed.
Target groups and social impact
The patient is the first to benefit from amore accurate proton therapy treatment. The use
of large margins added around the tumour to assure full coverage and to account for all
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uncertainty sources can be decreased by improving the accuracy of tissue segmentation
and mass-density conversion, and by using with proper in vivo verification methods.
Large margins imply that healthy tissue will be irradiated with a high dose, which can
lead to short and long term side effects, including the growth of secondary tumours, that
can have an considerable impact on the patient’s quality of life and life expectancy. For
this reason, proton therapy could be ideal for treating children and young adults. Many
questions about the potential of proton therapy are still unanswered, for which there is
an urgent need to perform clinical (and pre-clinical) trials and follow closely the patients
treated with different radiotherapy modalities for many decades.
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